Vir Biotechnology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Vir Biotechnology generated cash of -$778,785,000, which is less than the previous year. Cash used in financing activities reached the amount of $7,480,000 last year. Net change in cash is therefore -$606,676,000.
Cash Flow
| 2017 | -66.38M | -29.99M | 271.18M |
|---|---|---|---|
| 2018 | -94.09M | -60.44M | 24.97M |
| 2019 | -129.63M | -256.15M | 449.24M |
| 2020 | -190.94M | -9.86M | 529.47M |
| 2021 | -47.58M | -140.81M | 100.33M |
| 2022 | 1.66B | -1.19B | 34.76M |
| 2023 | -778.78M | 164.62M | 7.48M |
VIR Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 867.96M | 363.41M | 451.48M | 122.81M | 59.36M | 188.92M | 14.11M |
Operating activities | |||||||
Net income | -615.06M | 515.83M | 528.58M | -298.66M | -174.68M | -115.88M | -69.85M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 19.45M | 6.78M | 5.81M | 5.44M | 4.51M | 2.75M | 432K |
Stock-based compensation expense | 111.31M | 102.08M | 83.78M | 27.6M | 8.71M | 0 | 4.78M |
| Deferred income tax benefit | 111.31M | 102.08M | 83.78M | 27.6M | 8.71M | 0 | 4.78M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 770.03M | -773.07M | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 52.81M | 0 | 0 | 0 | 0 |
Accounts payable | 732K | 797K | -171K | -790K | 964K | 1.47M | 2.01M |
Cash generated by operating activities | -778.78M | 1.66B | -47.58M | -190.94M | -129.63M | -94.09M | -66.38M |
Investing activities | |||||||
Purchases Of Investments | -2.01B | -1.47B | -420.24M | -403.84M | -643.89M | -123.10M | 0 |
Investments In Property Plant And Equipment | -21.57M | -68.02M | -21.81M | -6.54M | -8.94M | -8.19M | -2.74M |
Acquisitions Net | 0 | 22K | 140.81M | 180K | 247.21M | 25K | -27.25M |
Cash generated by investing activities | 164.62M | -1.19B | -140.81M | -9.86M | -256.15M | -60.44M | -29.99M |
Financing activities | |||||||
Common Stock Issued | 7.76M | 28.46M | 100.59M | 529.91M | 126.41M | 0 | 271.18M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -3K | 0 | 0 |
Repayments of term debt | -287K | -260K | -259K | -250K | 4.37M | 0 | 0 |
Cash used in financing activities | 7.48M | 34.76M | 100.33M | 529.47M | 449.24M | 24.97M | 271.18M |
Net Change In Cash | -606.67M | 504.55M | -88.07M | 328.67M | 63.45M | -129.55M | 174.80M |
Cash at end of period | 261.29M | 867.96M | 363.41M | 451.48M | 122.81M | 59.36M | 188.92M |
| Data source | Data source | Data source | Data source | Data source |